[Study analysis evaluating the management and epidemiological aspects of the COVID-19 pandemic in Senegal one year on]. / Analyse de la gestion et des aspects épidémiologiques de l'épidémie COVID-19 au Sénégal à un an d'évolution.

Introduction: after a year of evolution, the COVID-19 pandemic continues to be a burden. The African continent has not had the high case and death rates from COVID-19 as was predicted early in the pandemic. However, coronavirus is placing severe strains on Africa´s health and economic sectors. Senegal, like other African countries, continues to face this pandemic. The purpose of this study is to evaluate the management strategy and the epidemiological profile of the pandemic in Senegal one year on. Methods: we listed all patients who tested positive for COVID-19 by RT-PCR throughout the country during the first year of the pandemic, from 2 March 2020 (first case date) to 1st March 2021. Epidemiological data were analysed. Results: a total of 34,732 positive cases were diagnosed and recorded in one year, with a case-fatality rate of 2.5%. All the country´s administrative regions had been affected. Dakar, the capital, was the epicentre of the pandemic. Male predominance was established on the basis of the number of positive cases and deaths. The average age of subjects was 47 years and the cure rate was 83.5%. People over 60 were the most vulnerable, particularly those with cardiovascular co-morbidities. Conclusion: Senegal´s strategy for managing COVID-19 has received international recognition. It has been dynamic, drawing on experience from previous management of public health events such as Ebola. The COVID-19 pandemic has put a strain on our fragile health systems. However, the response and the results achieved highlight the significant progress made by our country, helping to ensure the resilience of the health system.

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin.

In Africa, onchocerciasis and lymphatic filariasis (LF) are co-endemic in many areas. Current efforts to eliminate both diseases are through ivermectin-based mass drug administration (MDA). Years of ivermectin distribution for onchocerciasis may have interrupted LF transmission in certain areas. The Kédougou region, Senegal, is co-endemic for LF and onchocerciasis. Though MDA for onchocerciasis started in 1988, in 2014 albendazole had not yet been added for LF. The objective of this study was to assess in an integrated manner the LF and onchocerciasis status in the three districts of the Kédougou region after ≥10 years of ivermectin-based MDA. The study employed an African Programme for Onchocerciasis Control (APOC) onchocerciasis-related methodology. In the three districts, 14 villages close to three rivers that have Simulium damnosum breeding sites were surveyed. Convenience sampling of residents ≥5 years old was performed. Assessment for LF antigenemia by immunochromatographic testing (ICT) was added to skin snip microscopy for onchocerciasis. Participants were also tested for antibodies against Wb123 (LF) and Ov16 (onchocerciasis) antigens. In two districts, no participants were ICT or skin snip positive. In the third district, 3.5% were ICT positive and 0.7% were skin snip positive. In all the three districts, Wb123 prevalence was 0.6%. Overall, Ov16 prevalence was 6.9%. Ov16 prevalence among children 5-9 years old in the study was 2.5%. LF antigenemia prevalence was still above treatment threshold in one district despite ≥10 years of ivermectin-based MDA. The presence of Ov16 positive children suggested recent transmission of Onchocerca volvulus. This study showed the feasibility of integrated evaluation of onchocerciasis and LF but development of integrated robust methods for assessing transmission of both LF and onchocerciasis are needed to determine where MDA can be stopped safely in co-endemic areas.